SENTI BIOSCIENCES INC (SNTI) Stock News
NASDAQ:SNTI - Nasdaq - US81726A2096 - Common Stock - Currency: USD
SNTI Latest News, Press Relases and Analysis
Senti Bio to Host Conference Call and Webcast to Discuss SENTI-202 Clinical Data Being Presented at the American Association for Cancer Research (AACR) Annual Meeting 2025 on Monday, April 28th at 8:30 AM ET
SOUTH SAN FRANCISCO, Calif., April 24, 2025 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio” or the “Company”), a clinical-stage...
Senti Bio Participates in a Virtual Investor KOL Connect Segment
Moderated discussion with Stephen Strickland, MD, MSCI, internationally respected leukemia researcher, Director of Leukemia Research for Sarah Cannon...
Senti Bio (NASDAQ: SNTI) to Participate in a Live Virtual Investor Closing Bell Segment
Live moderated webcast with members of the Senti Bio management team on Wednesday, April 23rd at 4:00 PM ET...
Senti Bio Bolsters Scientific Advisory Board with Appointment of James B. Trager, Ph.D.
Industry leader in the development and application of cellular therapies, including CAR NK products, for cancer Led development of multiple clinical...
Senti Bio Appoints Feng Hsiung to Board of Directors
– Company also announced inducement grants under Nasdaq Listing Rule 5635(c)(4) –...
Senti Bio to Participate in Upcoming Investor Conferences
Senti Bio will participate in two upcoming investor conferences in September....
Senti Bio Joins Webull Corporate Connect Service Platform
Company advancing off-the-shelf CAR-NK cell therapy programs for oncology indications with lead candidate, SENTI-202, in clinical development for the...
Senti Bio to Showcase SENTI-202 Clinical Data and Novel Logic Gated Gene Circuit Mechanism of Action in Oral and Poster Presentations at the American Association for Cancer Research (AACR) Annual Meeting 2025
New data to be presented from Company’s lead product candidate SENTI-202 for the treatment of relapsed/refractory acute myeloid leukemia (r/r AML)...
Senti Bio Announces Fourth Quarter and Full Year 2024 Financial Results and Recent Pipeline and Corporate Highlights
– Previously reported MRD negative CR in 2 of 3 relapsed/refractory AML patients enrolled in first dose level and schedule of Phase 1 clinical trial of...
SNTI Stock Earnings: Senti Biosciences Reported Results for Q2 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Senti Biosciences (NASDAQ:SNTI) just reported results for the second quarter of...
SNTI Stock Earnings: Senti Biosciences Reported Results for Q2 2024
Senti Biosciences just reported results for the second quarter of 2024.
Senti Bio Announces Reverse Stock Split
Shares expected to begin trading on split-adjusted basis on July 18, 2024...
Senti Bio Strengthens Leadership Team with Strategic Hires
– Jay Cross, proven financial leader, appointed as CFO to drive strategic growth – – Faraz Siddiqui, expert in manufacturing operations, joins as SVP...
Senti Bio Announces Additional $11.5 Million of Financing
– Approximately $10 million additional investment in private placement equity financing – – $1.5 million from CIRM grant first announced in June 2024 – –...
Senti Bio Announces First Patient Dosed in Clinical Trial of SN301A in Hepatocellular Carcinoma in Collaboration with Celest Therapeutics
– Dose-finding clinical trial in China designed to evaluate safety and preliminary anti-tumor activity of SN301A (SENTI-301A manufactured in China) in...
Senti Biosciences Announces New Employment Inducement Grants
SOUTH SAN FRANCISCO, Calif., Dec. 03, 2024 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a clinical-stage biotechnology...
Senti Biosciences, Inc. Announces Oversubscribed $37.6 Million Private Placement Equity Financing
SOUTH SAN FRANCISCO, Calif., Dec. 02, 2024 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio” or the “Company”), a clinical-stage...
Senti Bio Announces Positive Initial Clinical Data in Phase 1 Clinical Trial of SENTI-202, a Logic Gated, Selective CD33/FLT3-Targeting CAR-NK Cell Therapy for the Treatment of Relapsed/Refractory Hematologic Malignancies Including AML
– 2 of 3 patients achieved MRD negative CR in the first dose level evaluated in the trial with a generally well-tolerated preliminary safety profile – ...
Senti Bio Announces Third Quarter 2024 Results and Recent Pipeline and Corporate Highlights
Enrollment continues in Phase 1 clinical trial of SENTI-202 for the treatment of relapsed/refractory hematologic malignancies including AML; initial...
Senti Bio Announces Second Quarter 2024 Results and Reviews Recent Corporate and Pipeline Highlights
– Dose finding ongoing in Phase 1 clinical trial of SENTI-202 for the treatment of relapsed/refractory hematologic malignancies including AML – –...
Senti Bio Announces Execution of Grant Award from California Institute for Regenerative Medicines (CIRM) for Clinical Development of SENTI-202
Senti Bio announced the commencement of a grant award of $8 million from the California Institute for Regenerative Medicines (CIRM)....
Senti Bio Announces Reverse Stock Split
Shares expected to begin trading on split-adjusted basis on July 18, 2024
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
Pre-market stock movers are worth diving into this morning as we break down all of the biggest news moving shares on Tuesday!
Senti Bio Awarded California Institute for Regenerative Medicines (CIRM) Grant for Clinical Development of Logic Gated CAR-NK Cell Therapy
$8M grant supports ongoing Phase 1 clinical trial of SENTI-202 for the treatment of relapsed/refractory hematologic malignancies including acute myeloid leukemia
Senti Bio Awarded California Institute for Regenerative Medicines (CIRM) Grant for Clinical Development of Logic Gated CAR-NK Cell Therapy
The California Institute for Regenerative Medicines (CIRM) has awarded an $8 million grant to Senti Bio to support clinical development of SENTI-202....
Why Is Beyond Air (XAIR) Stock Down 22% Today?
Beyond Air stock is down on Tuesday as investors in XAIR react to the company mixed earnings report for the first quarter of the year.